Pharmaceuticals, Biotechnology and Life Sciences
Amid Oasmia’s decision to report certain suspicious transactions that has been made by to company during several years, to the Swedish authority, Sven Rohmann, has today been appointed as acting CEO of the company, to replace the present CEO, Mikael Asp.
The new Oasmia board, led by Jörgen Olsson who was elected as the Chairman, independent Board member and former CEO of Hoist Finance, will review the business and proceedings of Oasmia in several aspects.
Oasmia Pharmaceutical has made a deal with Baxter BioPharma Solutions to manufacture Apealea in its site in Germany, so Oasmia can focus on other products in its own facilities.
Swedish Oasmia Pharmaceutical said on Tuesday that it got a patent for its unique nanotech method to produce novel pharmaceutical formulations, from the United States Patent and Trademark Office (USPTO).
A swedish oncology company Oasmia Pharmaceutical AB, which works on finding cancer cures for animals and humans, said it would move its veterinary assets to the United States.